DK2445502T4 - Heterocycliske forbindelser til behandling af neurologiske og psykologiske lidelser - Google Patents
Heterocycliske forbindelser til behandling af neurologiske og psykologiske lidelser Download PDFInfo
- Publication number
- DK2445502T4 DK2445502T4 DK10792677.6T DK10792677T DK2445502T4 DK 2445502 T4 DK2445502 T4 DK 2445502T4 DK 10792677 T DK10792677 T DK 10792677T DK 2445502 T4 DK2445502 T4 DK 2445502T4
- Authority
- DK
- Denmark
- Prior art keywords
- neurological
- treatment
- heterocyclic compounds
- psychological disorders
- psychological
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22048009P | 2009-06-25 | 2009-06-25 | |
US29308710P | 2010-01-07 | 2010-01-07 | |
PCT/US2010/039855 WO2010151689A1 (en) | 2009-06-25 | 2010-06-24 | Heterocyclic compounds for the treatment of neurological and psychological disorders |
Publications (2)
Publication Number | Publication Date |
---|---|
DK2445502T3 DK2445502T3 (da) | 2017-09-11 |
DK2445502T4 true DK2445502T4 (da) | 2022-11-28 |
Family
ID=43386893
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK10792677.6T DK2445502T4 (da) | 2009-06-25 | 2010-06-24 | Heterocycliske forbindelser til behandling af neurologiske og psykologiske lidelser |
Country Status (19)
Country | Link |
---|---|
US (10) | US8431576B2 (da) |
EP (3) | EP3309151A1 (da) |
JP (4) | JP5733841B2 (da) |
AU (1) | AU2010266018B2 (da) |
CA (1) | CA2766088C (da) |
CY (1) | CY1120054T1 (da) |
DK (1) | DK2445502T4 (da) |
ES (1) | ES2639065T5 (da) |
FI (1) | FI2445502T4 (da) |
HK (1) | HK1253046A1 (da) |
HR (1) | HRP20171415T4 (da) |
HU (1) | HUE033442T2 (da) |
LT (1) | LT2445502T (da) |
NZ (1) | NZ597107A (da) |
PL (1) | PL2445502T5 (da) |
PT (1) | PT2445502T (da) |
RS (1) | RS56352B2 (da) |
SI (1) | SI2445502T1 (da) |
WO (1) | WO2010151689A1 (da) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8686009B2 (en) * | 2009-06-25 | 2014-04-01 | Alkermes Pharma Ireland Limited | Prodrugs of NH-acidic compounds |
LT2445502T (lt) * | 2009-06-25 | 2017-09-25 | Alkermes Pharma Ireland Limited | Heterocikliniai junginiai, skirti neurologinių ir fiziologinių susirgimų gydymui |
WO2011084850A1 (en) * | 2010-01-07 | 2011-07-14 | Alkermes, Inc. | Prodrugs for the treatment of schizophrenia and bipolar disease |
US20110166128A1 (en) * | 2010-01-07 | 2011-07-07 | Alkermes, Inc. | Diaryldiazepine Prodrugs for the Treatment of Neurological and Psychological Disorders |
EP2521545B1 (en) | 2010-01-07 | 2019-11-27 | Alkermes Pharma Ireland Limited | Prodrugs of heteroaromatic compounds |
ES2647361T3 (es) | 2010-01-07 | 2017-12-21 | Alkermes Pharma Ireland Limited | Profármacos de sales de amonio cuaternario |
WO2011084851A1 (en) * | 2010-01-07 | 2011-07-14 | Alkermes, Inc. | Asenapine produrugs |
CA2797708C (en) | 2010-05-04 | 2016-08-16 | Alkermes Pharma Ireland Limited | Process for synthesizing oxidized lactam compounds |
AU2011270701B2 (en) | 2010-06-24 | 2015-05-14 | Alkermes Pharma Ireland Limited | Prodrugs of NH-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives |
SI2608670T1 (sl) | 2010-08-23 | 2019-04-30 | Alkermes Pharma Ireland Limited | Postopki za zdravljenje pridobivanja teže, ki je posledica uporabe antipsihotičnih zdravil |
US8754114B2 (en) | 2010-12-22 | 2014-06-17 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
EP2655314B1 (en) * | 2010-12-23 | 2018-02-07 | Alkermes Pharma Ireland Limited | Multi-api loading prodrugs |
CA2830511C (en) * | 2011-03-18 | 2021-09-14 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising aripiprazole lauroxil and sorbitan laurate |
JO3227B1 (ar) | 2011-09-08 | 2018-03-08 | Otsuka Pharma Co Ltd | مشتقات بنزو ثيوفين بها استبدال ببرازين كعوامل مضادة للذهان |
CA2853024C (en) | 2011-11-11 | 2017-08-22 | Pfizer Inc. | 2-thiopyrimidinones |
NZ722096A (en) | 2011-12-15 | 2016-11-25 | Alkermes Pharma Ireland Ltd | Prodrugs of secondary amine compounds |
CA2867121C (en) * | 2012-03-19 | 2021-05-25 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising fatty acid esters |
US9993556B2 (en) | 2012-03-19 | 2018-06-12 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising fatty glycerol esters |
US9999670B2 (en) | 2012-03-19 | 2018-06-19 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising benzyl alcohol |
ME03300B (me) | 2012-06-13 | 2019-07-20 | Incyte Holdings Corp | Supsтituisana triciklična jedinjenja као inhibiтori fgfr |
NZ702695A (en) | 2012-06-19 | 2015-10-30 | Debiopharm Int Sa | Prodrug derivatives of (e)-n-methyl-n-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide |
WO2014026125A1 (en) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Pyrazine derivatives as fgfr inhibitors |
EP3718536A1 (en) | 2012-09-19 | 2020-10-07 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions having improved storage stability |
US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
JP2014196292A (ja) * | 2013-03-07 | 2014-10-16 | 大塚製薬株式会社 | 医薬 |
DK2986610T5 (da) | 2013-04-19 | 2018-12-10 | Incyte Holdings Corp | Bicykliske heterocykler som fgfr-inhibitorer |
US10525057B2 (en) | 2013-09-24 | 2020-01-07 | Otsuka Pharmaceutical Co., Ltd. | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function |
MA39495A (fr) | 2014-03-20 | 2015-09-24 | Alkermes Pharma Ireland Ltd | Formulations d'aripiprazole présentant des vitesses d'injection plus élevées |
NZ767204A (en) | 2014-08-18 | 2024-02-23 | Alkermes Pharma Ireland Ltd | Aripiprazole prodrug compositions |
US10016415B2 (en) | 2014-08-18 | 2018-07-10 | Alkermes Pharma Ireland Limited | Aripiprazole prodrug compositions |
LT3185867T (lt) | 2014-08-25 | 2021-06-10 | Alkermes Pharma Ireland Limited | Apiprazolo darinių kristalizavimo procesas prailginto atpalaidavimo vaisto formose, skirtose šizofrenijos gydymui |
US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
EA038045B1 (ru) | 2015-02-20 | 2021-06-28 | Инсайт Корпорейшн | Бициклические гетероциклы в качестве ингибиторов fgfr |
WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
EP3292109A1 (en) | 2015-05-05 | 2018-03-14 | Pfizer Inc | 2-thiopyrimidinones |
CA3014788A1 (en) | 2016-02-17 | 2017-08-24 | Alkermes Pharma Ireland Limited | Compositions of multiple aripiprazole prodrugs |
US10751351B2 (en) | 2016-02-26 | 2020-08-25 | Debiopharm International S.A. | Medicament for treatment of diabetic foot infections |
WO2018104953A1 (en) * | 2016-12-07 | 2018-06-14 | Msn Laboratories Private Limited, R&D Center | Improved process for the preparation of 7-{4-[4-(2,3-dichlorophenyl)-piperazin-1-yl]butoxy}-2oxo-3,4-dihydro-2h-quinolin-1-yl)methyl dodecanoate |
US10815216B2 (en) * | 2016-12-14 | 2020-10-27 | Neuland Pharma Research Private Limited | Process for the preparation of aripiprazole lauroxil |
US20180265472A1 (en) * | 2017-03-17 | 2018-09-20 | Scinopharm Taiwan, Ltd. | Process for preparing aripiprazole lauroxil and intermediates thereof |
AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
US20200140410A1 (en) * | 2017-07-28 | 2020-05-07 | Interquim, S.A. | Process for the preparation of aripiprazole lauroxil |
CN107628999B (zh) * | 2017-10-25 | 2019-07-02 | 苏州华健瑞达医药技术有限公司 | 阿立哌唑十二烷酸酯的制备方法 |
CN110218209B (zh) * | 2018-03-02 | 2022-09-30 | 上海现代药物制剂工程研究中心有限公司 | 一种依匹哌唑月桂酸酯的晶型a、其制备方法及应用 |
EP3761983A1 (en) | 2018-03-05 | 2021-01-13 | Alkermes Pharma Ireland Limited | Aripiprazole dosing strategy |
EA202092649A1 (ru) | 2018-05-04 | 2021-06-21 | Инсайт Корпорейшн | Соли ингибитора fgfr |
US11466004B2 (en) | 2018-05-04 | 2022-10-11 | Incyte Corporation | Solid forms of an FGFR inhibitor and processes for preparing the same |
US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
US20220242825A1 (en) | 2019-07-12 | 2022-08-04 | Interquim, S.A. | Process for the preparation of aripiprazole lauroxil |
IL291901A (en) | 2019-10-14 | 2022-06-01 | Incyte Corp | Bicyclyl heterocycles as fgr suppressors |
WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
KR20220131900A (ko) | 2019-12-04 | 2022-09-29 | 인사이트 코포레이션 | Fgfr 억제제의 유도체 |
WO2021113479A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
EP4243768A1 (en) | 2020-11-12 | 2023-09-20 | Alkermes Pharma Ireland Limited | Immediate release multilayer tablet |
CN112656761B (zh) * | 2020-12-30 | 2023-09-08 | 河南合智医药科技有限公司 | 一种低刺激性阿立哌唑前药的油溶缓释注射制剂及其制备方法 |
AR126102A1 (es) | 2021-06-09 | 2023-09-13 | Incyte Corp | Heterociclos tricíclicos como inhibidores de fgfr |
Family Cites Families (135)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US528A (en) | 1837-12-20 | Improvement in cooking-stoves | ||
US5006A (en) | 1847-03-06 | Improvement in the process of manufacturing wire grating | ||
US2418499A (en) | 1944-06-20 | 1947-04-08 | Du Pont | 2-alkoxymethylmercapto-thiazoles and thiazolines and a process for preparing the same |
DE1070760B (de) * | 1955-11-19 | 1959-12-10 | Badische Anilin- S- Soda-Fabrik Aktiengesellschaft, Ludwigshafen / Rhein | Verfahren zur Herstellung von Azofarbstoffen |
GB849541A (en) | 1956-02-23 | 1960-09-28 | Rohm & Haas | Preparation of unsaturated cyclic urea derivatives |
DE1273533B (de) | 1962-09-08 | 1968-07-25 | Hoechst Ag | Verfahren zur Herstellung von N-(ª‡-Alkoxy-alkyl)-carbonsaeureamiden |
US3523121A (en) | 1967-03-09 | 1970-08-04 | Rohm & Haas | Certain 2-carbamoyl-3-isothiazolenes |
US3573308A (en) * | 1969-04-03 | 1971-03-30 | Hoffmann La Roche | 3-lower alkoxy methyl-3,4-dihydro-4-hydroxy-4-aryl quinazolin-2(1h) ones and related compounds |
US3957808A (en) | 1969-09-03 | 1976-05-18 | Rohm And Haas Company | 3-alkoxyisothiazoles |
US3998815A (en) | 1974-06-24 | 1976-12-21 | Interx Research Corporation | 1-hydrocarbonoyloxymethyl-3-carbamoyl or 3-carboethoxy-pyridinium salts |
US4204065A (en) | 1975-09-22 | 1980-05-20 | Interx Research Corporation | Soft quaternary surface active agents and method of using same |
JPS5331676A (en) | 1976-09-06 | 1978-03-25 | Mitsui Toatsu Chem Inc | Uracil derivatives and their preparation |
US4260769A (en) | 1977-04-22 | 1981-04-07 | Interx Research Corporation | 5,5-Diphenylhydantoins |
JPS54130587A (en) | 1978-03-30 | 1979-10-09 | Otsuka Pharmaceut Co Ltd | Carbostyryl derivative |
DE2960178D1 (en) | 1978-06-06 | 1981-04-09 | Hoechst Ag | New substituted phenylpiperazine derivatives, pharmaceutical compositions containing them and process for their preparation |
FI77852C (fi) | 1981-02-17 | 1989-05-10 | Otsuka Pharma Co Ltd | Foerfarande foer framstaellning av nya, saosom hjaertmediciner anvaendbara substituerade amid- och (maettad heterocykel)karbonylkarbostyrilderivat. |
AU532361B2 (en) | 1981-09-01 | 1983-09-29 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives |
DE3149010A1 (de) | 1981-12-10 | 1983-07-07 | A. Nattermann & Cie GmbH, 5000 Köln | (+)-2-(1-(2,6-dichlorphenoxy)-ethyl)-1,3- diazacyclopent-2-en, dessen herstellung und seine verwendung in pharamazeutischen praeparaten |
US4428935A (en) | 1982-05-24 | 1984-01-31 | Pfizer Inc. | Penicillanic acid dioxide prodrug |
IT1212743B (it) | 1983-05-17 | 1989-11-30 | Dompe Farmaceutici Spa | Sali quaternari di derivati di benzo[ 1,4 ]diazepinonici,pirido [1,4]benzodiazepinonici,prido [1,5]benzodiazepinonici e loro atti vita' farmacologica |
US4760057A (en) | 1983-06-23 | 1988-07-26 | Merck & Co., Inc. | (Acyloxyalkoxy)carbonyl derivatives as bioreversible prodrug moieties for primary and secondary amine functions in drugs |
DE3544134A1 (de) | 1984-12-15 | 1986-06-19 | Mitsubishi Chemical Industries Ltd., Tokio/Tokyo | Verfahren zur herstellung von n-((alpha)-alkoxyethyl) pyrrolidon |
JPS61171467A (ja) | 1985-01-23 | 1986-08-02 | Mitsubishi Chem Ind Ltd | N−(α−アルコキシエチル)ピロリドンの製造方法 |
AR240698A1 (es) | 1985-01-19 | 1990-09-28 | Takeda Chemical Industries Ltd | Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales |
GB8513754D0 (en) * | 1985-05-31 | 1985-07-03 | Jones T R | Anti-cancer quinazoline derivatives |
FR2587029B1 (fr) | 1985-09-11 | 1987-10-30 | Synthelabo | Derives de benzimidazole, leur preparation et leur application en therapeutique |
DK588486A (da) | 1985-12-09 | 1987-06-10 | Otsuka Pharma Co Ltd | Anvendelse af en forbindelse til behandling af hypoxi |
GB8607683D0 (en) * | 1986-03-27 | 1986-04-30 | Ici Plc | Anti-tumor agents |
MX173362B (es) * | 1987-03-02 | 1994-02-23 | Pfizer | Compuestos de piperazinil heterociclicos y procedimiento para su preparacion |
US4925860A (en) | 1987-08-05 | 1990-05-15 | E. I. Du Pont De Nemours And Company | Stable pharmaceutical composition of 3-(hydroxymethyl)-5,5-diphenylhydantoin disodium phosphate ester |
US4831031A (en) * | 1988-01-22 | 1989-05-16 | Pfizer Inc. | Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity |
GB8809978D0 (en) * | 1988-04-27 | 1988-06-02 | Ici Plc | Anti-tumour agents |
US5006528A (en) | 1988-10-31 | 1991-04-09 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives |
JP2608788B2 (ja) * | 1988-10-31 | 1997-05-14 | 大塚製薬 株式会社 | 精神***病治療剤 |
DK24089D0 (da) | 1989-01-20 | 1989-01-20 | Hans Bundgaard | Novel prodrug derivatives of biologically active agents containing hydroxyl groups or nh-acidic groups |
DE69021645T2 (de) | 1989-05-19 | 1996-02-22 | Hoechst Roussel Pharma | N-(aryloxyalkyl)heteroarylpiperidine und -heteroarylpiperazine, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikamente. |
US5350747A (en) | 1989-07-07 | 1994-09-27 | Pfizer Inc | Heteroaryl piperazine antipsychotic agents |
WO1991000863A1 (en) * | 1989-07-07 | 1991-01-24 | Pfizer Inc. | Heteroaryl piperazine antipsychotic agents |
US5041659A (en) | 1990-04-26 | 1991-08-20 | The Standard Oil Company | Synthesis of n-disubstituted amides by reaction of amides with certain organic hydroxyl compounds |
DK238190D0 (da) | 1990-10-03 | 1990-10-03 | Lundbeck & Co As H | Depotderivater |
US5206386A (en) | 1991-03-20 | 1993-04-27 | Isp Investments Inc. | Controlled release N-substituted pyrrolidone esters and process for the use thereof |
AU645681B2 (en) | 1991-05-02 | 1994-01-20 | John Wyeth & Brother Limited | Piperazine derivatives |
NZ240863A (en) | 1991-09-11 | 1995-04-27 | Mcneilab Inc | Substituted 4-aryl piperidine and 4-aryl piperazine derivatives, preparation and pharmaceutical compositions thereof |
TW226016B (da) * | 1991-12-30 | 1994-07-01 | Sterling Winthrop Inc | |
US5462934A (en) | 1992-03-09 | 1995-10-31 | Takeda Chemical Industries | Condensed heterocyclic ketone derivatives and their use |
EP0647133A4 (en) | 1992-06-12 | 1997-10-29 | Affymax Tech Nv | COMPOSITIONS AND METHODS FOR IMPROVED DRUG DELIVERY. |
JP3526575B2 (ja) | 1993-03-08 | 2004-05-17 | エーザイ株式会社 | ホスホン酸誘導体 |
US5497763A (en) | 1993-05-21 | 1996-03-12 | Aradigm Corporation | Disposable package for intrapulmonary delivery of aerosolized formulations |
US5508269A (en) | 1994-10-19 | 1996-04-16 | Pathogenesis Corporation | Aminoglycoside formulation for aerosolization |
DE4439493A1 (de) | 1994-10-25 | 1996-05-02 | Schering Ag | Neue Chinoxalindionderivate, deren Herstellung und Verwendung in Arzneimitteln |
JP3571795B2 (ja) | 1995-04-18 | 2004-09-29 | 株式会社日本触媒 | N−(1−アルキルオキシアルキル)カルバメート類の気相分子内脱アルコール反応用触媒およびn−ビニルカルバメート類の製造方法 |
PT889889E (pt) * | 1996-03-29 | 2007-01-31 | Duphar Int Res | Composto de piperazina e piperidina |
US6083922A (en) | 1996-04-02 | 2000-07-04 | Pathogenesis, Corp. | Method and a tobramycin aerosol formulation for treatment prevention and containment of tuberculosis |
JP4035642B2 (ja) | 1996-04-30 | 2008-01-23 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | リン酸2,5―ジオキソ―4,4―ジフェニル―イミダゾリジン―1―イルメチル エステルのジエステル合成の改良された方法 |
DE19619819A1 (de) | 1996-05-16 | 1997-11-20 | Boehringer Mannheim Gmbh | Neue Thiazolidindione, Verfahren zu ihrer Herstellung und diese enthaltenden Arzneimittel |
US5767068A (en) | 1997-02-13 | 1998-06-16 | Pathogenesis Corporation | Pure biologically active colistin, its components and a colistin formulation for treatment of pulmonary infections |
CA2288140C (en) * | 1997-04-25 | 2007-04-03 | Janssen Pharmaceutica N.V. | Farnesyltransferase inhibiting quinazolinones |
AU750207B2 (en) | 1997-06-13 | 2002-07-11 | Cydex Pharmaceuticals, Inc. | Polar drug or prodrug compositions with extended shelf-life storage and a method of making thereof |
AR016384A1 (es) * | 1997-07-30 | 2001-07-04 | Smithkline Beecham Corp | Inhibidores de caspasas, composiciones farmaceuticas que comprenden dichos inhibidores de caspasas y uso de los inhibidores de caspasas para prepararun medicamento util para el tratamiento de apoptosis y desordenes asociados con excesiva actividad de la convertosa il-1 beta. |
US6180095B1 (en) | 1997-12-17 | 2001-01-30 | Enzon, Inc. | Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents |
WO1999033846A2 (en) | 1997-12-31 | 1999-07-08 | The University Of Kansas | Water soluble prodrugs of secondary and tertiary amine containing drugs and methods of making thereof |
TR200100588T2 (tr) | 1998-08-26 | 2001-08-21 | Pharma Limited Aventis | Hücre yapışmasının önlenmesini modüle eden aza-bisikleler. |
FR2783519B1 (fr) | 1998-09-23 | 2003-01-24 | Sod Conseils Rech Applic | Nouveaux derives d'amidines, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant |
US6444668B1 (en) * | 1999-05-04 | 2002-09-03 | Wyeth | Combination regimens using progesterone receptor modulators |
US6509334B1 (en) * | 1999-05-04 | 2003-01-21 | American Home Products Corporation | Cyclocarbamate derivatives as progesterone receptor modulators |
MY128450A (en) | 2000-05-24 | 2007-02-28 | Upjohn Co | 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives |
EP1368327B1 (en) * | 2001-02-14 | 2004-10-20 | Warner-Lambert Company LLC | Benzo thiadiazine matrix metalloproteinase inhibitors |
WO2002096351A2 (en) | 2001-04-03 | 2002-12-05 | Aryx Therapeutics | Ultrashort-acting opioids for transdermal application |
ES2316777T3 (es) | 2002-02-15 | 2009-04-16 | Glaxo Group Limited | Moduladores de receptores vainilloides. |
EP1485085A4 (en) * | 2002-03-20 | 2007-03-14 | Bristol Myers Squibb Co | PHOSPHATE PRODRUGS OF FLUORO XINDOLS |
US7115587B2 (en) | 2002-08-20 | 2006-10-03 | Bristol-Myers Squibb Company | Aripiprazole complex formulation and method |
JP2006503106A (ja) * | 2002-09-17 | 2006-01-26 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | 統合失調症を処置するためのヘテロ環式置換ピペラジン |
RU2005112254A (ru) | 2002-10-24 | 2006-01-20 | Пфайзер Продактс Инк. (Us) | Ацильные производные 5-(1,2-бензизотиазол-3-ил)-1-пиперазинил)этил)-6-хлор-1,3-дигидро-2н-индол-2-она, обладающие нейролептической активностью |
DE10303669A1 (de) | 2003-01-28 | 2004-07-29 | Hans-Knöll-Institut für Naturstoff-Forschung e.V. | Tetraalkylammoniumsalze vom Kohlensäureestertyp, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen |
EA012240B1 (ru) | 2003-04-03 | 2009-08-28 | Семафор Фармасьютикалз, Инк. | Пролекарства ингибиторов киназы pi-3 |
MXPA05012538A (es) | 2003-05-23 | 2006-02-22 | Otsuka Pharma Co Ltd | Derivados de carbostirilo y estabilizantes del estado de animo para trastornos del mismo. |
US20050032811A1 (en) * | 2003-08-06 | 2005-02-10 | Josiah Brown | Methods for administering aripiprazole |
US7160888B2 (en) | 2003-08-22 | 2007-01-09 | Warner Lambert Company Llc | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia |
WO2005066165A1 (en) | 2003-12-31 | 2005-07-21 | Warner-Lambert Company Llc | N-substituted piperidine and piperazine derivatives |
AR047530A1 (es) * | 2004-02-04 | 2006-01-25 | Novartis Ag | Formas de sal de 4-(4-metilpiperazin-1-ilmetil)-n-(4-metil-3-(4-piridin-3-il)pirimidin-2-ilamino)fenil)-benzamida |
JP2007522200A (ja) | 2004-02-13 | 2007-08-09 | ファイザー・プロダクツ・インク | 非定型抗精神病薬とコルチコトロピン放出因子拮抗薬の治療的組合せ |
US7169803B2 (en) | 2004-03-15 | 2007-01-30 | Bristol-Myers Squibb Company | N-substituted prodrugs of fluorooxindoles |
JP4840594B2 (ja) * | 2004-03-23 | 2011-12-21 | 日産化学工業株式会社 | 抗不整脈薬としての3環性ベンゾピラン化合物 |
US7119214B2 (en) * | 2004-04-13 | 2006-10-10 | Cephalon France | Thio-substituted tricyclic and bicyclic aromatic methanesulfinyl derivatives |
WO2006037090A2 (en) | 2004-09-28 | 2006-04-06 | Purdue Research Foundation | Drug-phosphate conjugates as prodrugs |
WO2006090273A2 (en) | 2005-02-22 | 2006-08-31 | Warner-Lambert Company Llc | [1,8]naphthyridin-2-ones and related compounds with keto or hydroxyl linkers for the treatment of schizophrenia |
TWI320783B (en) | 2005-04-14 | 2010-02-21 | Otsuka Pharma Co Ltd | Heterocyclic compound |
EP1777222A1 (en) | 2005-09-22 | 2007-04-25 | Galantos Pharma GmbH | Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment |
CN101300256A (zh) | 2005-10-31 | 2008-11-05 | 辉瑞产品公司 | 7-[4-(4-萘-1-基-哌嗪-1-基)-丁氧基]-3,4-二氢-1h-[1,8]萘啶-2-酮的结晶盐 |
US20070185069A1 (en) | 2005-11-14 | 2007-08-09 | Plum Stacy M | Anti-angiogenic activity of 2-methoxyestradiol in combination with anti-cancer agents |
CA2636077C (en) * | 2006-01-18 | 2012-01-03 | Amgen Inc. | Thiazole compounds as protein kinase b (pkb) inhibitors |
TW200804359A (en) * | 2006-01-19 | 2008-01-16 | Speedel Experimenta Ag | Substituted 4-phenylpiperidines |
US20090068290A1 (en) | 2006-08-31 | 2009-03-12 | Michel Bourin | Bifeprunox doses for treating schizophrenia |
BRPI0715445A2 (pt) | 2006-08-31 | 2014-05-13 | Solvay Pharm Bv | Uso de um composto de bifeprunox, e, kit de titulação |
US20080085888A1 (en) | 2006-09-15 | 2008-04-10 | Breining Scott R | Therapeutic Combinations |
MX2009006007A (es) | 2006-12-05 | 2009-07-17 | Neurogesx Inc | Profarmacos y metodos para hacer y usar los mismos. |
WO2008076447A2 (en) | 2006-12-15 | 2008-06-26 | Ordway Research Institute | Treatments of therapy-resistant diseases comprising drug combinations |
TWI325694B (en) | 2006-12-15 | 2010-06-01 | Ind Tech Res Inst | All digital delay locked loop |
US20080186971A1 (en) | 2007-02-02 | 2008-08-07 | Tarari, Inc. | Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic |
CA2681506C (en) | 2007-03-19 | 2016-05-24 | Perry Peters | Combinations of 5-ht2a inverse agonists and antagonists with antipsychotics |
CA2833209C (en) | 2007-04-27 | 2016-06-28 | Purdue Pharma L.P. | Piperidine and piperazine compounds as trpv1 antagonists |
AU2008254585B2 (en) | 2007-05-21 | 2013-09-26 | Reviva Pharmaceuticals, Inc. | Compositions, synthesis, and methods of using quinolinone based atypical antipsychotic agents |
AR066760A1 (es) | 2007-05-30 | 2009-09-09 | Wyeth Corp | Derivados heteroarilo de benzodioxanos heterociclo-fusionados antidepresivos, composiciones farmaceuticas, procesos de obtencion |
WO2009003136A1 (en) * | 2007-06-26 | 2008-12-31 | Rigel Pharmaceuticals, Inc. | Substituted pyrimidine-2, 4 -diamines for treating cell proliferative disorders |
US20100292316A1 (en) | 2007-07-18 | 2010-11-18 | Research Development Foundation | Improved therapeutic methods and compositions comprising chroman ring compounds |
US8076334B2 (en) * | 2007-09-20 | 2011-12-13 | Hoffmann-La Roche Inc. | Prodrugs of thyroid hormone analogs |
WO2009052467A1 (en) | 2007-10-19 | 2009-04-23 | Board Of Regents Of The University Of Texas System | Methods of identifying pi-3-kinase inhibitor resistance |
DK2389372T3 (da) * | 2009-01-23 | 2015-12-14 | Rigel Pharmaceuticals Inc | Sammensætninger og fremgangsmåder til hæmning af jak-reaktionsvejen |
US9307454B2 (en) * | 2009-02-09 | 2016-04-05 | Qualcomm Incorporated | Method and apparatus for maintaining location continuity for a UE following handover |
LT2445502T (lt) * | 2009-06-25 | 2017-09-25 | Alkermes Pharma Ireland Limited | Heterocikliniai junginiai, skirti neurologinių ir fiziologinių susirgimų gydymui |
US8686009B2 (en) | 2009-06-25 | 2014-04-01 | Alkermes Pharma Ireland Limited | Prodrugs of NH-acidic compounds |
MY155570A (en) * | 2009-06-26 | 2015-10-30 | Novartis Ag | 1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17 |
WO2011084850A1 (en) | 2010-01-07 | 2011-07-14 | Alkermes, Inc. | Prodrugs for the treatment of schizophrenia and bipolar disease |
ES2647361T3 (es) | 2010-01-07 | 2017-12-21 | Alkermes Pharma Ireland Limited | Profármacos de sales de amonio cuaternario |
US20110166128A1 (en) | 2010-01-07 | 2011-07-07 | Alkermes, Inc. | Diaryldiazepine Prodrugs for the Treatment of Neurological and Psychological Disorders |
WO2011084851A1 (en) | 2010-01-07 | 2011-07-14 | Alkermes, Inc. | Asenapine produrugs |
EP2521545B1 (en) | 2010-01-07 | 2019-11-27 | Alkermes Pharma Ireland Limited | Prodrugs of heteroaromatic compounds |
CA2797708C (en) * | 2010-05-04 | 2016-08-16 | Alkermes Pharma Ireland Limited | Process for synthesizing oxidized lactam compounds |
CN102260290A (zh) | 2010-05-25 | 2011-11-30 | 苏州波锐生物医药科技有限公司 | 喹喏啉酮类化合物及其在制备精神病药物中的用途 |
US8530413B2 (en) * | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
AU2011270701B2 (en) * | 2010-06-24 | 2015-05-14 | Alkermes Pharma Ireland Limited | Prodrugs of NH-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives |
SI2608670T1 (sl) * | 2010-08-23 | 2019-04-30 | Alkermes Pharma Ireland Limited | Postopki za zdravljenje pridobivanja teže, ki je posledica uporabe antipsihotičnih zdravil |
EP2655314B1 (en) * | 2010-12-23 | 2018-02-07 | Alkermes Pharma Ireland Limited | Multi-api loading prodrugs |
CA2830511C (en) * | 2011-03-18 | 2021-09-14 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising aripiprazole lauroxil and sorbitan laurate |
NZ722096A (en) | 2011-12-15 | 2016-11-25 | Alkermes Pharma Ireland Ltd | Prodrugs of secondary amine compounds |
CA2867121C (en) * | 2012-03-19 | 2021-05-25 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising fatty acid esters |
US9999670B2 (en) * | 2012-03-19 | 2018-06-19 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising benzyl alcohol |
US9993556B2 (en) * | 2012-03-19 | 2018-06-12 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising fatty glycerol esters |
EP3718536A1 (en) * | 2012-09-19 | 2020-10-07 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions having improved storage stability |
DK2970101T3 (da) | 2013-03-14 | 2018-08-20 | Alkermes Pharma Ireland Ltd | Pro-drugs af fumarater og deres anvendelse i behandling af forskellige sygdomme |
US8669281B1 (en) | 2013-03-14 | 2014-03-11 | Alkermes Pharma Ireland Limited | Prodrugs of fumarates and their use in treating various diseases |
US10525057B2 (en) * | 2013-09-24 | 2020-01-07 | Otsuka Pharmaceutical Co., Ltd. | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function |
MA39495A (fr) * | 2014-03-20 | 2015-09-24 | Alkermes Pharma Ireland Ltd | Formulations d'aripiprazole présentant des vitesses d'injection plus élevées |
US10016415B2 (en) * | 2014-08-18 | 2018-07-10 | Alkermes Pharma Ireland Limited | Aripiprazole prodrug compositions |
CA3014788A1 (en) * | 2016-02-17 | 2017-08-24 | Alkermes Pharma Ireland Limited | Compositions of multiple aripiprazole prodrugs |
-
2010
- 2010-06-24 LT LTEP10792677.6T patent/LT2445502T/lt unknown
- 2010-06-24 CA CA2766088A patent/CA2766088C/en active Active
- 2010-06-24 US US12/823,007 patent/US8431576B2/en active Active
- 2010-06-24 EP EP17176623.1A patent/EP3309151A1/en active Pending
- 2010-06-24 HU HUE10792677A patent/HUE033442T2/en unknown
- 2010-06-24 RS RS20170927A patent/RS56352B2/sr unknown
- 2010-06-24 AU AU2010266018A patent/AU2010266018B2/en active Active
- 2010-06-24 ES ES10792677T patent/ES2639065T5/es active Active
- 2010-06-24 HR HRP20171415TT patent/HRP20171415T4/hr unknown
- 2010-06-24 EP EP10792677.6A patent/EP2445502B2/en active Active
- 2010-06-24 WO PCT/US2010/039855 patent/WO2010151689A1/en active Application Filing
- 2010-06-24 NZ NZ597107A patent/NZ597107A/en unknown
- 2010-06-24 DK DK10792677.6T patent/DK2445502T4/da active
- 2010-06-24 SI SI201031536T patent/SI2445502T1/sl unknown
- 2010-06-24 PT PT107926776T patent/PT2445502T/pt unknown
- 2010-06-24 JP JP2012517738A patent/JP5733841B2/ja active Active
- 2010-06-24 EP EP22195630.3A patent/EP4124616A1/en active Pending
- 2010-06-24 PL PL10792677.6T patent/PL2445502T5/pl unknown
- 2010-06-24 FI FIEP10792677.6T patent/FI2445502T4/fi active
-
2012
- 2012-09-07 US US13/607,066 patent/US8796276B2/en active Active
-
2014
- 2014-06-05 US US14/297,195 patent/US20140350254A1/en not_active Abandoned
- 2014-12-26 JP JP2014264706A patent/JP6093341B2/ja active Active
-
2015
- 2015-04-02 US US14/677,333 patent/US20150274670A1/en not_active Abandoned
-
2016
- 2016-05-05 US US15/147,021 patent/US10023537B2/en active Active
- 2016-12-02 JP JP2016235293A patent/JP6546896B2/ja active Active
-
2017
- 2017-09-13 CY CY20171100963T patent/CY1120054T1/el unknown
-
2018
- 2018-01-19 US US15/875,478 patent/US10112903B2/en active Active
- 2018-09-14 US US16/131,773 patent/US10351529B2/en active Active
- 2018-09-27 HK HK18112426.9A patent/HK1253046A1/zh unknown
-
2019
- 2019-05-29 US US16/425,119 patent/US10822306B2/en active Active
- 2019-06-24 JP JP2019116369A patent/JP7042239B2/ja active Active
-
2020
- 2020-09-14 US US17/020,499 patent/US11518745B2/en active Active
-
2022
- 2022-10-31 US US18/051,216 patent/US20230150941A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2445502T4 (da) | Heterocycliske forbindelser til behandling af neurologiske og psykologiske lidelser | |
DK2207550T3 (da) | Tetrahydroquinolinderivater til behandling af post-traumatiske stress-lidelser | |
DK3456707T3 (da) | 4-(p-quinonyl)-2-hydroxybutanamidderivater til behandling af mitokondriesygdomme | |
GB0703909D0 (en) | Treatment of anxiety disorders | |
DK2440230T3 (da) | Behandlingsregimener til behandling af neurologisk sygdom | |
DK2019683T4 (da) | Indgivelse af vækstfaktorer til behandling af CNS-lidelser | |
DK2796469T3 (da) | Hidtil ukendte sammensætninger og fremgangsmåder til behandling af IgE-medierede forstyrrelser | |
DK2545939T3 (da) | Tetrahydrobiopterin til behandling af tilstande associeret med forhøjede phenylalaninniveauer | |
DK2451482T3 (da) | Kombinationsterapi til behandlingen af diabetes | |
DK2240135T3 (da) | Apparat til behandling af fedme og reflukssygdom | |
RS55071B1 (sr) | Tretman poremećaja koji su u vezi sa bdnf primenom lakvinimoda | |
DK2445912T3 (da) | Ny forbindelse anvendelig til behandlingen af degenerative og inflammatoriske sygdomme | |
DK2356093T3 (da) | Carbazolforbindelser og terapeutiske anvendelser af forbindelserne | |
IL218143A0 (en) | Substituted heterocyclic derivatives for the treatment of pain and epilepsy | |
DK2632954T4 (da) | Midler og fremgangsmåder til behandling af dlbcl | |
DK2114447T3 (da) | Forebyggelse og behandling af subkliniks pcvd | |
DK2285808T3 (da) | Spiroindolderivater til behandling af parasitsygdomme | |
DK2004204T3 (da) | Behandling af neurodegenerative sygdomme med selenat | |
DK2310003T3 (da) | Inhibitorer af Carnitin-Palmitoyl-Transferase-1 til behandling og forebyggelse af lidelser forårsaget af delipidering af neuralt væv | |
DK2117565T3 (da) | Anvendelse af chitosaner til behandlingen af negleinflammatoriske sygdomme | |
DK3061766T3 (da) | Sammensætninger og fremgangsmåder til behandlingen af sygdomme der involverer epitelcelleapoptose | |
DK3106166T3 (da) | Forbindelser til behandling af smertesyndrom og andre lidelser | |
DK2285416T3 (da) | Konjugat til behandlingen af mesotheliom | |
DK2109449T3 (da) | Lægemiddel til behandling af endometriose | |
DK2310017T3 (da) | Nifurtimox til behandling af sygdomme fremkaldt af trichomonadida |